JP2018507860A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507860A5
JP2018507860A5 JP2017544759A JP2017544759A JP2018507860A5 JP 2018507860 A5 JP2018507860 A5 JP 2018507860A5 JP 2017544759 A JP2017544759 A JP 2017544759A JP 2017544759 A JP2017544759 A JP 2017544759A JP 2018507860 A5 JP2018507860 A5 JP 2018507860A5
Authority
JP
Japan
Prior art keywords
amino acid
binding domain
seq
protein
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017544759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507860A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/019401 external-priority patent/WO2016138164A1/en
Publication of JP2018507860A publication Critical patent/JP2018507860A/ja
Publication of JP2018507860A5 publication Critical patent/JP2018507860A5/ja
Pending legal-status Critical Current

Links

JP2017544759A 2015-02-26 2016-02-24 抗原特異的ｔ細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物 Pending JP2018507860A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121406P 2015-02-26 2015-02-26
US62/121,406 2015-02-26
PCT/US2016/019401 WO2016138164A1 (en) 2015-02-26 2016-02-24 A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses

Publications (2)

Publication Number Publication Date
JP2018507860A JP2018507860A (ja) 2018-03-22
JP2018507860A5 true JP2018507860A5 (enExample) 2018-12-20

Family

ID=56789742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017544759A Pending JP2018507860A (ja) 2015-02-26 2016-02-24 抗原特異的ｔ細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物

Country Status (10)

Country Link
US (1) US9775898B2 (enExample)
EP (1) EP3261667A4 (enExample)
JP (1) JP2018507860A (enExample)
KR (1) KR20170105107A (enExample)
CN (1) CN107249629A (enExample)
BR (1) BR112017018017A2 (enExample)
IL (1) IL254110A0 (enExample)
RU (1) RU2017129818A (enExample)
TW (1) TWI674269B (enExample)
WO (1) WO2016138164A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715651A (zh) * 2016-09-19 2019-05-03 生控基因疫苗股份有限公司 乙型肝炎治疗型疫苗
WO2019133647A1 (en) * 2017-12-29 2019-07-04 Thevax Genetics Vaccine Co., Ltd. Combination of a fusion protein vaccine with anti-ox40 antibody for use in eliciting antigen-specific immune responses
CN113527511A (zh) * 2018-09-19 2021-10-22 天康生物股份有限公司 融合蛋白及其制备方法、应用、表达系统和疫苗
CN109663126A (zh) * 2019-03-01 2019-04-23 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
US20210100887A1 (en) * 2019-10-04 2021-04-08 Reber Genetics Co., Ltd. Recombinant fusion protein and immunogenic composition
CN112972671B (zh) * 2019-12-13 2024-04-19 远大赛威信生命科学(南京)有限公司 药物组合物及其用途
US11213581B2 (en) * 2020-04-10 2022-01-04 Akston Biosciences Corporation Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
CN115956086A (zh) * 2020-05-06 2023-04-11 萨摩亚商柏沛生医股份有限公司 用于针对癌症及传染病的免疫疗法的融合蛋白
CN111548395A (zh) * 2020-05-25 2020-08-18 中国农业科学院兰州兽医研究所 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用
CN112626073B (zh) * 2020-10-26 2021-06-15 中国科学院昆明动物研究所 一种对PRRSV具有特异性免疫刺激作用的CpG-ODN及其应用
EP4442272A4 (en) * 2021-12-28 2025-07-02 Chengdu Maxvax Biotechnology LLC VACCINE ADJUVANT, ITS PREPARATION PROCESS AND ITS USE
CN114835822B (zh) * 2022-04-22 2022-11-04 浙江洪晟生物科技股份有限公司 猪瘟病毒的多聚体疫苗及其制备方法
WO2025180443A1 (en) * 2024-02-29 2025-09-04 Immunadd Inc. Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ253137A (en) * 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
CA2340174C (en) * 1998-08-10 2011-01-04 Antigenics Llc Compositions of cpg and saponin adjuvants and methods thereof
HRP20050660A2 (en) * 2003-01-29 2006-02-28 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
WO2004069206A2 (en) 2003-02-04 2004-08-19 University Of Connecticut Health Center Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
AU2003272065A1 (en) * 2003-04-03 2004-10-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
CN101594878A (zh) * 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗
EP2078726A1 (en) * 2008-01-09 2009-07-15 Vision 7 GmbH Secretable HIV entry inhibitory peptides for therapy of HIV infection
EP2237794B1 (en) * 2008-01-31 2013-04-10 TheVax Genetics Vaccine Co., Ltd. Chimeric hiv fusion proteins as vaccines
CN102202689A (zh) 2008-08-28 2011-09-28 葛兰素史密丝克莱恩生物有限公司 疫苗
EP2416798B1 (en) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
BR112013004353B1 (pt) 2010-08-26 2022-04-26 Toray Industries, Inc Composições imunogênicas
CN109535259A (zh) * 2012-12-05 2019-03-29 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN105517573A (zh) 2013-07-03 2016-04-20 辛格利科医药品有限公司 合成用于绿脓杆菌疫苗的低聚糖
US20150037374A1 (en) * 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
CN109715651A (zh) * 2016-09-19 2019-05-03 生控基因疫苗股份有限公司 乙型肝炎治疗型疫苗

Similar Documents

Publication Publication Date Title
JP2018507860A5 (enExample)
RU2017129818A (ru) Композиция вакцины, содержащая иммуногенный белок и комбинированные адъюванты, для применения в стимулировании антигенспецифичных т-клеточных ответов
EP2928491B1 (en) Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
JP2016199557A5 (enExample)
AU2012356969B2 (en) Vaccines against HPV
JP2016510983A5 (enExample)
JP2015509707A5 (enExample)
Donaldson et al. Virus-like particles, a versatile subunit vaccine platform
JP2014530003A5 (enExample)
JP2016519658A5 (enExample)
JP2015212284A5 (enExample)
JP2021502807A5 (enExample)
IL274130B1 (en) HIV–1 vaccine immunogens with novel scaffolds
CN107847575A (zh) 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物
JP2016520534A5 (enExample)
JP2018501258A5 (enExample)
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
RU2007147938A (ru) Конъюгаты антигенов и их применение
ES3030310T1 (en) Sars-cov-2 subunit vaccine
WO2010088393A3 (en) Li-kay hybrid peptides that modulate the immune response to influenza
CU24751B1 (es) Antígeno recombinante para la inducción de respuesta inmune contra el virus zika
NZ751943A (en) Hepatitis c virus immunogenic compositions and methods of use thereof
TH114418A (th) วัคซีน